2021. Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) in 6 US communities
Session: Poster Abstract Session: Antimicrobial Resistant Infections: Treatment
Saturday, October 29, 2016
Room: Poster Hall

Antibiotic resistance profiles of CRE infections pose a substantial treatment challenge. We described the antibiotics being used to treat CRE infections and assessed effective antibiotic use.


CDC’s Emerging Infections Program performs active population-based laboratory surveillance for CRE. CRE cases are defined by isolation, from urine or a normally-sterile site, of Escherichia coli, Klebsiella spp., or Enterobacter spp. non-susceptible to carbapenems (except ertapenem) and resistant to all third-generation cephalosporins tested. Six EIP sites piloted an assessment of antibiotic therapy for 3 months in 2014 to evaluate treatment in the 14 days after specimen collection. Antibiotic class, timing of antibiotic relative to specimen collection date, and effective antibiotic use (based on susceptibility documented in the medical record) were evaluated.


Of the 105 incident cases, 11 (10%) were invasive infections and 94 (90%) had positive urinary cultures alone. Klebsiella pneumoniae was the most common organism (59%). Most patients (80%) received an antibiotic within 14 days after specimen collection, most commonly fluoroquinolones (21%). Of the 71 patients assessed for effective antibiotic use, 48 (68%) received an effective antibiotic within 14 days of specimen collection, most commonly aminoglycosides (26%). Median time to any antibiotic was 0 days (range: 0-11 days), whereas median time to first effective antibiotic was 3 days (range: 0-12 days). Effective therapy was similar in invasive infections (75%) and urinary isolates (66%). 19 patients (42%) received an effective antibiotic as initial therapy, most commonly fluoroquinolones. 26 patients (58%) received their effective antibiotic after sensitivities became available, most commonly aminoglycosides.


Nearly a third of patients with CRE who received antibiotics did not receive an effective antibiotic within 14 days of their specimen collection date. Although most patients received an antibiotic on the date of specimen collection, the median time to first effective antibiotic was 3 days after specimen collection. For patients with CRE infections, rapid susceptibility testing may help guide prompt, effective treatment.

Chris Bower, MPH1,2,3, Sujan C. Reddy, MD4, Lucy Wilson, MD, ScM5, Elisabeth Vaeth, MPH5, Ghinwa Dumyati, MD, FSHEA6, Cathleen Concannon, MPH6, Erin C. Phipps, DVM, MPH7,8, Nicole Kenslow, MPH8,9, Marion Kainer, MBBS, MPH, FSHEA10, Daniel Muleta, MD, MPH10, Jacquelyn Mounsey, BSN, RN, CCRP10,11, Wendy Bamberg, MD12, Sarah J. Janelle, MPH, CIC12, Elizabeth Badolato, AAS12, Jessica Reno, MPH1,2,13 and Jesse T. Jacob, MD3,4, (1)Atlanta Veterans Affairs Medical Center, Decatur, GA, (2)Atlanta Research and Education Foundation, Decatur, GA, (3)Georgia Emerging Infections Program, Decatur, GA, (4)Emory University School of Medicine, Atlanta, GA, (5)Maryland Department of Health and Mental Hygiene, Baltimore, MD, (6)New York Rochester Emerging Infections Program at the University of Rochester Medical Center, Rochester, NY, (7)University of New Mexico, Albuquerque, NM, (8)New Mexico Emerging Infections Program, Albuquerque, NM, (9)Health Sciences Center, University of New Mexico, Albuquerque, NM, (10)Tennessee Department of Health, Nashville, TN, (11)Vanderbilt University, Nashville, TN, (12)Colorado Department of Public Health and Environment, Denver, CO, (13)Georgia Emerging Infections Program, Atlanta, GA


C. Bower, None

S. C. Reddy, None

L. Wilson, None

E. Vaeth, None

G. Dumyati, None

C. Concannon, None

E. C. Phipps, None

N. Kenslow, None

M. Kainer, None

D. Muleta, None

J. Mounsey, None

W. Bamberg, None

S. J. Janelle, None

E. Badolato, None

J. Reno, None

J. T. Jacob, None

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.